• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • COVID-19 Patient Resource Center
    • Clinical Trials
    • Search Clinical Trials
    • Patient Notification System
    • What is Clinical Research?
    • Volunteering for a Clinical Trial
    • Understanding Informed Consent
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Clinical Trial Listings
    • Market Research
    • FDA Approved Drugs
    • Training Guides
    • Books
    • eLearning
    • Events
    • Newsletters
    • White Papers
    • SOPs
    • eCFR and Guidances
  • White Papers
  • Trial Listings
  • Advertise
  • COVID-19
  • iConnect
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » Directories » FDA Approved Drugs » Vitrakvi (larotrectinib)

AND
  • A
  • B
  • C
  • D
  • E
  • F
  • G
  • H
  • I
  • J
  • K
  • L
  • M
  • N
  • O
  • P
  • Q
  • R
  • S
  • T
  • U
  • V
  • W
  • X
  • Y
  • Z

Vitrakvi (larotrectinib)

  • Profile

Profile

Contact Information

Contact: Bayer
Website: www.vitrakvi-us.com

Currently Enrolling Trials

    Show More

    General Information

    Vitrakvi (larotrectinib) is a kinase inhibitor. 

    Vitrakvi is specifically indicated for the treatment of adult and pediatric patients with solid tumors that:

    • have a neurotrophic receptor tyrosine kinase (NTRK) gene fusion without a known acquired resistance mutation,
    • are metastatic or where surgical resection is likely to result in severe morbidity, and
    • have no satisfactory alternative treatments or that have progressed following treatment.

    Vitrakvi is supplied as both a capsule and an oral solution. The recommended dose regimen is as follows:

    Adult and Pediatric Patients with Body Surface Area of at Least 1.0 Meter-Squared:

    • Vitrakvi 100 mg orally twice daily, with or without food, until disease progression or until unacceptable toxicity.

    Pediatric Patients with Body Surface Area Less Than 1.0 Meter-Squared:

    • Vitrakvi 100 mg/m2 orally twice daily, with or without food, until disease progression or until unacceptable toxicity. 

    Mechanism of Action

    Vitrakvi (larotrectinib) is a kinase inhibitor. Research suggests that the NTRK genes can become abnormally fused to other genes, producing a TRK fusion protein that can lead to the growth and survival of solid tumors in various sites of the body.

    Side Effects

    Adverse effects associated with the use of Vitrakvi may include, but are not limited to, the following:

    • fatigue
    • nausea
    • dizziness
    • vomiting
    • increased AST
    • cough
    • increased ALT
    • constipation
    • diarrhea

    Clinical Trial Results

    This indication is approved under accelerated approval based on overall response rate and duration of response. Continued approval for this indication may be contingent upon verification and description of clinical benefit in confirmatory trials. 

    The FDA approval of Vitrakvi was based on pooled data across a Phase I adult trial, the Phase II NAVIGATE trial and the Phase I/II pediatric SCOUT trial (N=55). In pooled study results, Vitrakvi demonstrated an overall response rate (ORR) of 75% by blinded independent review committee, with 22% of patients achieving a complete response and 53% achieving a partial response across various tumor types, including soft tissue sarcoma, salivary gland, infantile fibrosarcoma, thyroid, lung, melanoma, colon, GIST, cholangiocarcinoma, appendix, breast and pancreas. Seventy-three percent of responding patients (N=41) had a duration of response (DOR) lasting six months or greater at the time of data cut-off. Median DOR (range 1.6+, 33.2+) and progression-free survival (PFS) had not been reached at the time of analysis. Median time to response was 1.84 months.

    Approval Date: 2018-11-01
    Company Name: Bayer
    Back to Listings

    Upcoming Events

    • 16Feb

      Fundamentals of FDA Inspection Management: Reduce Anxiety, Increase Inspection Success

    • 21May

      WCG MAGI Clinical Research Conference – 2023 East

    Featured Products

    • Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

      Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

    • Surviving an FDA GCP Inspection

      Surviving an FDA GCP Inspection: Resources for Investigators, Sponsors, CROs and IRBs

    Featured Stories

    • Revamp-360x240.png

      Califf Calls for Major Evidence Generation Revamp, Experts’ Opinions Differ

    • AskTheExpertsGreen-360x240.png

      Ask the Experts: Managing Investigational Products

    • SurveywBlueBackground-360x240.png

      Survey Outlines Site Challenges, Successes on Diversity

    • PatientCentricity-360x240.png

      Site Spotlight: DM Clinical Shows Patient Centricity Doesn’t Have to Break the Bank

    Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

    The information you need to adapt your monitoring plan to changing times.

    Learn More Here
    • About Us
    • Contact Us
    • Privacy Policy
    • Do Not Sell or Share My Data

    Footer Logo

    300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

    Phone 617.948.5100 – Toll free 866.219.3440

    Copyright © 2023. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing